Repligen Reports Strong Q1 2025 Financial Results

Repligen ( (RGEN) ) has released its Q1 earnings. Here is a breakdown of the information Repligen presented to its investors.

Repligen Corporation is a global life sciences company specializing in bioprocessing technologies, primarily serving biopharmaceutical drug developers and contract development and manufacturing organizations worldwide. The company is headquartered in Waltham, Massachusetts, with manufacturing sites across the U.S. and Europe.

Repligen reported strong financial results for the first quarter of 2025, with a revenue of $169 million, marking a 10% year-over-year increase. The company also noted a 14% organic non-COVID growth, reflecting its robust business momentum and strategic acquisitions.

Key financial highlights include a 72% year-over-year increase in adjusted operating income and a nearly 20% growth in total orders. The company also closed the acquisition of 908 Devices’ bioprocessing portfolio, enhancing its process analytical technology offerings. Additionally, Repligen launched the CTech™ SoloVPE® Plus System, a new product aimed at improving accuracy and ease of use in bioprocessing.

The company maintains a positive outlook for the year, reiterating its full-year organic revenue growth guidance of 9.5% to 13.5%. Repligen remains confident in its ability to navigate the current economic environment, with minimal expected impact from tariffs on its earnings per share.